Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 12:22PM ET
1.04
Dollar change
+0.15
Percentage change
16.73
%
Index- P/E- EPS (ttm)- Insider Own31.05% Shs Outstand8.32M Perf Week-55.17%
Market Cap10.81M Forward P/E- EPS next Y-1.16 Insider Trans1.42% Shs Float7.17M Perf Month-58.89%
Income- PEG- EPS next Q-0.29 Inst Own12.63% Short Float0.35% Perf Quarter-73.09%
Sales- P/S- EPS this Y89.16% Inst Trans-12.48% Short Ratio0.80 Perf Half Y-47.73%
Book/sh0.27 P/B3.91 EPS next Y17.20% ROA- Short Interest0.03M Perf Year-81.97%
Cash/sh0.73 P/C1.43 EPS next 5Y- ROE- 52W Range0.77 - 6.50 Perf YTD-71.35%
Dividend Est.- P/FCF- EPS past 5Y47.65% ROI- 52W High-84.00% Beta0.59
Dividend TTM- Quick Ratio1.03 Sales past 5Y16.82% Gross Margin- 52W Low34.47% ATR (14)0.29
Dividend Ex-Date- Current Ratio1.03 EPS Y/Y TTM80.07% Oper. Margin-562.84% RSI (14)22.64 Volatility31.04% 13.48%
Employees11 Debt/Eq0.60 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.75
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q85.34% Payout- Rel Volume77.77 Prev Close0.89
Sales Surprise-100.00% EPS Surprise16.36% Sales Q/Q-100.00% EarningsNov 03 AMC Avg Volume31.81K Price1.04
SMA20-56.22% SMA50-62.85% SMA200-64.01% Trades Volume1,160,206 Change16.73%
Feb-29-24 09:36AM
08:30AM
Feb-22-24 08:30AM
Feb-14-24 08:30AM
Feb-07-24 08:30AM
08:30AM Loading…
Jan-17-24 08:30AM
Jan-04-24 08:30AM
Dec-15-23 08:35AM
Dec-13-23 08:30AM
Dec-12-23 01:02PM
09:24AM
Nov-28-23 08:30AM
Nov-09-23 08:30AM
Nov-06-23 08:30AM
Nov-03-23 04:07PM
04:01PM Loading…
04:01PM
04:00PM
Oct-17-23 08:30AM
Oct-12-23 10:19AM
07:20AM
Oct-09-23 12:10PM
Oct-05-23 04:09PM
Oct-04-23 08:30AM
08:00AM
Oct-03-23 08:30AM
Sep-28-23 09:30AM
Sep-25-23 09:30AM
Sep-18-23 09:30AM
Sep-16-23 09:00PM
Aug-31-23 09:30AM
06:44AM Loading…
Aug-16-23 06:44AM
Aug-11-23 04:07PM
04:01PM
Aug-04-23 06:23AM
Aug-03-23 08:03AM
Jul-26-23 01:30PM
Jun-29-23 06:30AM
Jun-28-23 06:30AM
Jun-20-23 05:50AM
May-24-23 06:30AM
May-23-23 06:30AM
May-11-23 05:39PM
05:20PM
Apr-24-23 04:01PM
Apr-20-23 08:38AM
Apr-17-23 06:30AM
Apr-12-23 06:30AM
Apr-03-23 06:30AM
Mar-31-23 04:01PM
Mar-22-23 06:30AM
Mar-08-23 06:30AM
Mar-06-23 06:30AM
Mar-01-23 06:30AM
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. Its immuno-oncology focused platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bartoszek Raymond J.DirectorDec 06Buy4.502501,12517,206Dec 06 06:21 PM
Bartoszek Raymond J.DirectorDec 05Buy4.501,0004,50016,956Dec 06 06:21 PM
Bartoszek Raymond J.DirectorDec 04Buy4.331,0004,32515,956Dec 06 06:21 PM
Iadonato ShawnChief Executive OfficerNov 29Buy3.514,10014,403675,230Nov 30 05:21 PM
PHILIPS CRAIG W.PresidentNov 28Buy3.273,0009,81260,811Nov 30 05:27 PM
Iadonato ShawnChief Executive OfficerNov 28Buy3.339002,995671,130Nov 30 05:21 PM
Foote Marion RDirectorOct 11Option Exercise0.144,443622143,204Oct 12 04:25 PM
PHILIPS CRAIG W.PresidentSep 21Buy2.402,9006,97057,811Sep 21 04:58 PM
Iadonato ShawnChief Executive OfficerSep 20Buy2.5010,00025,042670,230Sep 21 04:57 PM
Kenny PaulineGeneral Counsel & SecretarySep 20Buy2.581,5003,87018,448Sep 21 04:57 PM
PHILIPS CRAIG W.PresidentSep 20Buy2.546001,52554,911Sep 21 04:58 PM
Bartoszek Raymond J.DirectorSep 19Buy2.372,0004,74514,956Sep 21 04:56 PM
Baker KeithChief Financial OfficerSep 18Buy2.135,00010,67216,880Sep 19 05:03 PM
Bartoszek Raymond J.DirectorSep 18Buy2.082,5005,20012,956Sep 19 05:02 PM
Bartoszek Raymond J.DirectorSep 15Buy2.185001,09010,456Sep 19 05:02 PM
Guillaudeux ThierryChief Scientific OfficerSep 14Buy2.0010,00020,00021,696Sep 15 06:49 PM
Baker KeithChief Financial OfficerJun 16Buy2.925,00014,60011,880Jun 16 04:28 PM
Bartoszek Raymond J.DirectorJun 14Option Exercise0.1460,0188,403844,478Jun 16 04:29 PM
Iadonato ShawnChief Executive OfficerJun 14Option Exercise0.141,382193667,669Jun 16 04:29 PM
PHILIPS CRAIG W.PresidentJun 14Option Exercise0.141,38219334,654Jun 16 04:31 PM
Iadonato ShawnChief Executive OfficerMar 20Sale3.291,1193,678666,287Mar 21 07:15 PM
PHILIPS CRAIG W.PresidentMar 20Sale3.298722,86666,977Mar 21 07:16 PM
Kenny PaulineGeneral Counsel & SecretaryMar 20Sale3.295441,78817,806Mar 21 07:15 PM
Iadonato ShawnChief Executive OfficerMar 17Sale4.941,5807,808667,406Mar 21 07:15 PM
PHILIPS CRAIG W.PresidentMar 17Sale4.941,2316,08667,849Mar 21 07:16 PM
Kenny PaulineGeneral Counsel & SecretaryMar 17Sale4.947673,79318,350Mar 21 07:15 PM